吳俠 副教授 博士生導(dǎo)師

電子郵箱：wuxia@ecust.edu.cn

通訊地址：上海市徐匯區(qū)梅隴路130號華東理工大學(xué)科輔助七樓

個人簡介：

2008年7月畢業(yè)于內(nèi)蒙古大學(xué)，獲理學(xué)博士學(xué)位，留校工作；2009年月赴美國猶他州立大學(xué)從事博士后研究；2011-2019年在內(nèi)蒙古大學(xué)省部共建草原家畜生殖調(diào)控與繁育國家重點實驗室，擔(dān)任干細胞與重編程課題組組長；2019年調(diào)入華東理工大學(xué)藥學(xué)院。曾先后主持國家重大研發(fā)計劃、國家“863”高科技計劃、國家自然等國家和省部級項目。先后獲得省部級杰出青年基金、青年創(chuàng)新創(chuàng)業(yè)人才、“青年科技英才計劃”青年科技骨干等人才類稱號。完成成果鑒定1項，申請發(fā)明專利30余項，其中PCT專利2項，授權(quán)專利7項，參與教材和論著的編著3部，發(fā)表研究論文30余篇。擔(dān)任中國整形美容協(xié)會干細胞研究與應(yīng)用分會理事（上海）、中國細胞生物學(xué)會會員。

研究方向與成果：

主要從事基因治療藥物的研發(fā)和臨床轉(zhuǎn)化研究。以遺傳代謝罕見病、關(guān)節(jié)疾病、老年退行性疾病、癌癥等為研究對象，利用腺病毒和腺相關(guān)病毒作為遞送工具，探討疾病的作用機制，設(shè)計、優(yōu)化藥物載體，進行藥理學(xué)、毒理學(xué)研究，進而推進基因治療藥物的臨床轉(zhuǎn)化。2019年與中國醫(yī)學(xué)科學(xué)院天津血液病醫(yī)院合作，開展了亞洲首個血友病B基因治療藥物臨床研究。2022年5月，該研究成果發(fā)表于國際血液學(xué)頂級期刊《The Lancet Haematology》，被評為2022年中國血液學(xué)十大研究進展。該研究中的一位受試者在無外部輸血情況下，完成全膝關(guān)節(jié)置換手術(shù)，該研究在世界上首次證實基因治療后能夠完全恢復(fù)血友病B患者的凝血功能，并發(fā)表于《The New England Journal of Medicine》。2023年，《原創(chuàng)基因治療技術(shù)研發(fā)與新型血友病診療體系的建立和推廣》獲得天津市科技進步一等獎。此外，開發(fā)的四個溶酶體貯積癥基因治療藥物已經(jīng)開展臨床轉(zhuǎn)化，并表現(xiàn)出明顯的安全性和有效性。

教材與專著：

《動物解剖學(xué)、組織學(xué)與生殖生物學(xué)簡明教程》，內(nèi)蒙古大學(xué)出版社，2016.7，ISBN978-7-5665-1016-7

《動物種業(yè)科技創(chuàng)新戰(zhàn)略研究報告》，科學(xué)出版社，2015.6，ISBN978-03-044229-1

《哺乳動物生殖工程學(xué)》，科學(xué)出版社，2018.10，ISBN978-7-03-058921-7

發(fā)表論文（#第一作者；*通訊作者）：

1. Zhang Yanan^#, Tang Dingyue^#, Wang Li, Yang Jing, Wu Xia^*, Xiao Xiao^*, Wang Jianshe^*. Prevention of Portal-Tract Fibrosis in Zfyve19-/- Mouse Model with Adeno-Associated Virus Vector Delivering ZFYVE19. Hum Gene Ther. 2023 Sep 6. doi: 10.1089/hum.2023.041

2. Zhou Kaiyi^#, Yuan Meng, Sun Jiabao, Zhang Feixu, Zong Xiaoying, Li Zhanao, Tang Dingyue, Zhou Lichen, Zheng Jing, Xiao Xiao^*, Wu Xia^*. Sildenafil increases AAV9 transduction after a systemic administration and enhances AAV9-dystrophin therapeutic effect in mdx mice. Gene Ther. 2023 Jul 27. doi: 10.1038/s41434-023-00411-3

3. Xue Feng^#, Li Huiyuan^#, Wu Xia^#, Liu Wei^#, Zhang Feixu, Tang Dingyue, Chen Yunfei, Wang Wentian, Chi Ying, Zheng Jing, Du Zengmin, Jiang Wei, Zhong Chen, Wei Jun, Zhu Ping, Fu Rongfeng, Liu Xiaofan, Chen Lingling, Pei Xiaolei, Sun Junjiang, Cheng Tao^*, Yang Renchi^*, Xiao Xiao^*, Lei Zhang^*. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol. 2022, 9(7):e504-e513

4. Zhong Chen^#, Chen Zifeng, Xia Yong, Wu Jun, Zhang Feixu, Cheng Cheng, Wu Xia^*, Zhuang Yingping, Xiao Xiao^*. Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways. Mol Ther Methods Clin Dev. 2022, 27;25:461-475

5. Zhong Chen^#, Jiang Wei, Wang Yefan, Sun Junjiang, Wu Xia^*, Zhuang Yingping, Xiao Xiao^*. Repeated systemic dosing of AAV vectors in immunocompetent mice after blockade of T-cell costimulatory pathways, Human Gene Therapy, 2022, 33(5-6):290-300

6. Wu Jiamei^#, Zhao Kai^#, Du Zengmin, Chen Ying, Zhang Feixu, Jiang Wei, Zheng Jing*, Wu Xia^*, Shen Chengyong^*, Xiao Xiao^*. Systemic effect of FHL1 on neuromuscular junction and myotube formation via insulin-like growth factor and myostatin signaling pathways. Biochem Biophys Res Commun. 2021, 22;537:125-131

7. Wu X^#,*, Hu S, Wang L, Li Yan, Yu H^*.Dynamic changes of histone acetylation and methylation inbovine oocytes, zygotes, and preimplantation embryos.J ExpZool (Mol Dev Evol). 2020;1-12.

8. Tao D^#, Liang J^#, Pan Y, Zhou Y, Feng Y, Zhang L, Xu J, Wang H, He P, Yao J, Zhao Y, Ning Q, Wang W, Jiang W, Zheng J, Wu X^*.  In Vitro and In Vivo Study on the Effect of Lysosome-associated Protein  Transmembrane 4 Beta on the Progression of Breast Cancer. J Breast Cancer. 2019.27;22(3):375-386.

9. Wei Z^#, Yang Z^#, Wu X^*, Yang H^*.  Screening of exosomal miRNAs derived from subcutaneous and visceral  adipose tissues: underlying targets for treatment of obesity and  associated metabolic disorders. Molecular Medicine Reports.  2018;18(3):3314-332

10. Wang Jinze^#, Zhang Feixu^#, Yang Huidi, Wu Huikuan, Cui Rong, Zhao Yunjie, Jiao Cuihua, Wang Xianxin, Liu Xin, Wu Liqiong, Li Guangpeng, Wu Xia^*. Effect of TEAD4 on multilineage differentiation of muscle-derived stem cells. Am J Transl Res. 2018; 10(3): 998-1011.

11. Li S^#, Lu X^#, He H, Cui R, Wang X, Wang X, Wu X^*.A novel culture system robustly maintained pluripotency of embryonic stem cells and accelerated somatic reprogramming by activating Wnt signaling. Am J Transl Res. 2017;9(10):4534-4544.

12. Wu X^#,*, Song M, Yang X, Liu X, Liu K, Jiao C, Wang J, Bai C, Sun G, Liu X, Li G^*. et al. Establishment of bovine embryonic stem cells after knockdown of CDX2. Sci. Rep. 6, 28343; doi: 10.1038/srep28343 (2016).

13. Wu X^#, Ouyang H^#, Duan B, Pang D, Zhang L, Yuan T, Xue L, Ni D, Cheng L, Dong S, Wei Z, Li L, Yu M, Sun Q, Chen D, Lai L, Dai Y, Li G^*. Production of cloned transgenic cow expressing omega-3 fatty acids. Transgenic Res. 2012;21(3):537-43.

14. Wu X^#, Li Y, Xue L, Wang L, Yue Y, Li K, Bou S, Li G, Yu H^*. Multiple histone site epigenetic modifications in nuclear transfer and in vitro fertilized bovine embryos. Zygote. 2011 Feb;19(1):31-45